Successful use of immune checkpoint inhibitors and recent clinical developments of the inhibitors of the IDO1 enzyme instigate scientists to develop potent small molecule-based IDO1 inhibitors that will adequately address this cancer immunotherapeutic approach. The gene discussed is IDO1; the disease is cancer.